Improving the health of EU citizens

How the RISET project will benefit Transplant Patients

New Tools

New diagnostic and clinical tools developed by the Consortium Partners will **benefit transplant patients** as they allow the clinical team to make **better decisions about the status of the patient's health.** The research has led to better tools for monitoring the immune status of transplant patients **allowing their doctor to identify problems before they happen.**

The same approach means that some patients may be able to benefit from **reduced immunosuppression** if they are shown to be at a lesser risk

Better use of Organs

The researchers have developed ways to prepare an organ and prevent damage to it before transplantation. **Patients will benefit from having a healthier transplant less likely to fail.** This, in turn, means that there will be **more organs available to help other people who need a transplant.**

Cost Savings

Patients will benefit from the **cost savings gained** by **reduced drug use**, **better quality of transplanted organs**, and **early detection of rejection** as **more money** will become available to **extend transplant programmes in the Europe**.

Towards Personalised Medicine

The development of Biological Markers (A biomarker is something in the body that can be measured in order to tell doctors how a treatment is working or how a disease is progressing) will **benefit patients by allowing individualised patient treatment,** i.e. tailor made therapy, which will **reduce drug side effects and improve the quality of life** for patients as the treatment they receive **will be unique to their needs**.

New treatment protocols

New treatment protocols currently under investigation in clinical trials may provide an **advanced cell therapy approach** which would allow a **patient at risk of blood cancer to rapidly reconstitute their immune system** after a stem cell transfusion. This may mean that **high risk patients are likely to remain free of the disease and have reduced chances of other infections, allowing them to remain healthy without immunosuppression.**

Data Analysis and Research

Data gathered and analysed throughout the project will be used to support the clinical use of Tregs (T regulatory cells) in renal transplant patients. Treg therapy could enable the **reduction or withdrawal of immunosuppressive drugs** leading to a **better quality of life for patients** as their organ will **remain healthy without the need for as many drugs.**

Information and Interaction

Patients have **access to up to date information** via the **RISET website and newsletters.** Their **views and experiences have been sought** and reported on throughout the project. Patients and Patient Organisations have had the opportunity to **interact with the researchers / clinicians in a meaningful way**. Other work undertaken by the consortium has **made an impact** in the areas of **ethics and legal issues relating to the introduction of cell therapies which will benefit patients**. For instance, the **Consortium has used its expertise** to contribute to **public consultation papers** on issues such as Advanced Therapy Medicinal Products and to **raise awareness of the issues facing transplant recipients** at public, scientific and clinical meetings.

Optimal patient care

Patients involved in clinical trials **benefit from clinical control measures**, including blood and urine analysis, which **contribute to them receiving optimal care.**